Barbara Weiser, M.D.


Infectious Diseases


  • Professor in Residence, Department of Medicine


To see if Barbara Weiser is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

VA Northern CA Health Care System

10535 Hospital Way
Mather, CA 95655
Driving Directions

Primary Phone:

Additional Phone Numbers

Clinic Phone: 916-843-7000
Clinic Fax: 916-843-7009
Department Phone: 916-734-3815
Department Referral Phone: 916-843-2849
Physician Referrals: 800-4-UCDAVIS (800-482-3284)



Philosophy of Care

My philosophy of care is based on communication with patients. I listen to and focus on the patient.

Research/Academic Interests

Dr. Weiser's research interests include: HIV research, in particular research on HIV tropism, pathogenesis and disease progression in infected individuals.

Technology Transfer

Dr. Weiser is an inventor of six  patented technologies issued between 2004 and 2011 for the analysis of  HIV 1 tropism in the clinical care of HIV-1-infected patients. Licensed to Quest Diagnostics, Inc, these technologies serve as the basis for Quest’s clinical test, "HIV-1 Coreceptor Tropism Assay."  The patents and licenses are owned by Health Research Inc.


Infectious Diseases


M.D., University of Pittsburgh School of Medicine, Pittsburgh PA 1975

A.B., Vassar College, Poughkeepsie NY 1969

Internship: Bellevue Hospital New York University Medical Center, New York NY 1975-1976


Bellevue Hospital New York University Medical Center, New York NY 1976-1978


Infectious Diseases, Memorial Sloan-Kettering Cancer Center, New York NY 1978-1980

Molecular Virology, Stanford University School of Medicine, Stanford CA 1984-1985

Molecular Virology, UC San Francisco, San Francisco CA 1980-1983

Board Certifications

American Board of Internal Medicine, 1978

Professional Memberships

American Society of Microbiology

Infectious Disease Society of America

International AIDS Society

Honors and Awards

American Cancer Society Postdoctoral Research Fellowship, 1981

NIH Clinical Investigator Award, 1982

Mary Pangborn Award for Research with an Impact on Clinical Medicine, New York State Dept of Health, 1997

Select Recent Publications

Weber S, Weiser B, Kemal  KS,  Burger H, Ramirez, CR,  Korn K, Anastos K, Kaul R, Kovacs C,  Doerfler  W. Epigenetic  analysis  of HIV-1  proviral  genomes from infected individuals: predominance of unmethylated CpG’s. Virology, 2014;449:181-189.

Kemal KS,  Kitchen C, Burger H, Klimkait T,  Hamy F, Foley B, Mayers D, Anastos K, Petrovic K, Suchard M, Minin V, Weiser B. Recombination between variants from genital tract and plasma: evolution of multidrug resistant HIV-1. AIDS Res and Hum Retroviruses; 2012;28:1766-74.

Shi B, Kitchen C,  Weiser B, Mayers D , Foley B, Kemal K, Anastos K,  Suchard M, Parker M, Brunner  C, Burger  H.  Evolution  and  recombination of  genes  encoding  HIV-1 drug resistance and coreceptor usage during antiretroviral therapy, Virology, 2010;404:5-20.

Weiser  B,  Philpott  S,  Klimkait  T, Burger H, Kitchen C, Bürgisser P, Gorgievski M, Perrin L, Piffaretti J-C, Ledergerber  B, and  the Swiss HIV Cohort Study. HIV-1 coreceptor usage and CXCR4-specific viral  load  predict  clinical  disease  progression  during combination  antiretroviral therapy. AIDS; 2008;22:469-479.

Kemal KS,   Burger  H,   Mayers D,  Anastos  K, Foley B, Kitchen C, Huggins P, Schroeder T, Picchio G, Back S, Gao W, Meyer WA III, Weiser B.  HIV-1 drug  resistance  in variants from the female genital tract and plasma. J Infect Dis. 2007;195:535-545.

Kemal KS, Foley B, Burger H, Anastos K, Minkoff H, Kitchen C, Philpott S, Gao W, Robison E, Holman S, Dehner C, Beck S, Meyer W, Landay A, Kovacs A, Bremer J, Weiser B.  HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation.  Proc Natl Acad Sci USA. 2003;100:12972-12977.

Philpott S, Weiser B, Anastos K, Kitchen CMR, Robison E, Meyer WA, Sacks HS, Mathur-Wagh U, Brunner C, and Burger H. Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy. J Clin Invest. 2001;107:431-438.

Fang G, Burger H, Grimson R, Tropper P, Nachman S, Mayers D, Weislow O, Moore R, Reyelt C, Hutcheon N, Baker D, and Weiser B. Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission. Proc Natl Acad Sci USA. 1995;92:12100-12104.

Weiser B, Nachman S, Tropper P, Viscosi KH, Grimson R, Baxter G, Fang G, Reyelt C, Hutcheon N, and Burger H. Quantitation of human immunodeficiency virus type 1 during pregnancy: relationship of viral titer to mother-to-child transmission and stability of viral load. Proc Natl Acad Sci USA. 1994;91:8037-8041.

Burger H, Weiser B, Flaherty K, Gulla J, Nguyen P, and Gibbs RA. Evolution of human immunodeficiency virus type 1 nucleotide sequence diversity among close contacts.  Proc Natl Acad Sci USA. 1991;88:11236-11240.